An interventional study of restoration of proximal cavities of primary molars with flowable giomer and restoration of proximal cavities of primary molars with highly viscous glass ionomer cement in Dental Caries Class II, sponsored by Ain Shams University. Recruiting at 1 site in Egypt. Open to participants aged 4 Years to 8 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-13.
Sponsored by Ain Shams University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Dental Caries by Ain Shams University — 5 open to participants now, 7 under way, none of them phase 3. Dental Caries · Ain Shams University.
Among the 17 studies in Dental Caries by Ain Shams University, this one is the 2nd largest by planned enrollment of the 15 interventional ones that give a count, is one of 4 that started in 2022, is one of 12 with no phase, and was the 8th registered.
1,176 studies on the registry are indexed under Dental Caries; 209 are open to participants now.
Browse Dental Caries studies →5 of the 17 studies in Dental Caries by Ain Shams University are open now, in 1 country. Recruiting first, the newest first:
Ain Shams University · Sites in Egypt
Ages 15–25
Ain Shams University · Sites in Egypt
Ages 6–8 · Healthy volunteers
Ain Shams University · Sites in Egypt
Ages 4–8 · Healthy volunteers
Ain Shams University · Sites in Egypt
Ages 18–50 · Healthy volunteers
By country, each count listing its studies:
Of the 86 Dental Caries studies recruiting now, 18 (21%) set no upper age limit and 66 (77%) stop at 75 or younger; 60 take children under 18; 53 take healthy volunteers.
This study: 4 Years to 8 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 4 started in 2022.
This study's planned enrollment of 124 is above the median of 60 across 967 interventional studies indexed under Dental Caries.
Median enrollment 40 across the 15 interventional studies, 276 across the 2 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ain Shams University is the lead sponsor of 1,958 studies on the registry; 432 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
1 of the studies in Dental Caries by Ain Shams University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05943782Ain Shams UniversityEvaluation of CAD/CAM Onlays Fabricated by Subtractive Versus Additive Digital Manufacturing Techniques. | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Dental Caries by Ain Shams University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the present study is to assess Flowable Giomer Beautifil Flow Plus X (Shofu Dental Corporation, Japan) and Glass-hybrid-added HVGIC, Equia Forte (GC Corporation, Tokyo,
Japan) in class II cavities of primary molars regarding the following objectives:
The primary objective To evaluate and compare the clinical performance of Flowable Giomer Beautifil Flow Plus X (Shofu Dental Corporation, Japan) and Glass-hybrid-added HVGIC, Equia Forte (GC Corporation, Tokyo, Japan) in restoring class II cavities of primary molars after 3,6, and 12 months. The secondary objective To assess the effect of different independent variables on the treatment outcome of the experimental restorative materials.
Research question:
Is there a difference in the clinical performance between flowable giomers and highly viscous glass ionomer in restoring class II cavities of primary molars?
Null Hypothesis There is no difference in the clinical performance between Flowable Giomer Beautifil Flow Plus X (Shofu Dental Corporation, Japan) and Glass-hybrid-added HVGIC, Equia Forte (GC Corporation, Tokyo, Japan) after one year of follow up.
Study design:
The study will be two parallel-arm, double blinded randomized, controlled clinical trial with an equal allocation ratio.
Study Setting:
The study will be conducted at Pediatric dentistry and Dental Public Health Department, Faculty of Dentistry, Ain Shams University.
Ethical Considerations:
Sample Size:
Sample size estimation was based on testing the null hypothesis that there is no difference between the clinical success rates of the two materials by setting α error of 5%, power of 80%, and allocation ratio 1:1. Results from previous studies suggested that the one-year clinical success rate of EQUIA Forte™ in class II restorations in primary molars was 74.4% (24) , while that for Beautifil flow plus x was estimated to be 94.1% based upon the findings of a previous study regarding Giomer in class II cavities. Based on this, the needed sample is 53 primary molars per group. Considering 15% drop-out rate, the needed sample size was increased to 62 molars per group. Sample size calculation was performed using G*Power software version 3.1.9.4 for MS Windows Study Population A total of 124 primary molars fulfilling the eligibility criteria will be restored in eligible participants, with one of the two tested restorative materials.
Study grouping:
The study will include two groups:
Group I (experimental): 62 primary molars will be restored with flowable Giomer beautifil flow plus x Group II (comparator): 62 primary molars will be restored with high-viscosity glass ionomer cement (EQUIA Forte)
Randomization and blinding:
Randomization will be performed using the Computer generated random number table to ensure that each primary molar had an equal chance of being assigned to either the glass ionomer group or the giomer group. Randomization will be done by tooth such that participants with multiple eligible carious primary molars were allowed to draw a corresponding number of cards. This trial will be double-blinded such that all participants, the clinical evaluator and the data analyst will be blinded to the type of the applied restorative materials in all periods of the study.
Allocation concealment:
The randomization groups will be written on a paper and each of the papers will be numbered and will be individually packed by another person than the investigator in an opaque envelope after folding each paper eight folds. All participants will be asked to select an opaque sealed envelope for each of their carious primary molars to avoid allocation bias. The numbers in the envelopes determined the group assigned for each molar. The investigator will open the sealed envelope after the cavity preparation and then assigns the treatment group accordingly.
Implementation:
A. Sequence generation will be done by a trial independent subject. B. Recruitment and screening of participants will be done by the main investigator, while enrolling of primary molars for the trial will be decided by two calibrated dentists.
Participants and assessors will be blinded at baseline and follow up. The primary investigator will not be blinded. C. Envelops will be kept with a trial independent subject and the allocated treatment will be revealed after cavity preparation
Study population:
Patients attending the Department of Pediatric Dentistry and dental public health, Faculty of Dentistry, at Ain Shams University for routine dental care will be examined clinically and radiographically with bite-wing radiography. Patients will be assessed for eligibility for participation.
Study Procedure
A detailed case history will be recorded, and an oral examination will be done. Oral prophylaxis will be performed to all the study children before the restorative treatment. A total of 124 primary molars (first/second, maxillary/mandibular) with carious lesions that indicated for restorative treatment will be selected by specified inclusion criteria. Based on the type of restorative material, the teeth will be randomly allocated to two groups (n = 62 in each group) Initial bite-wing radiographs of the teeth to be treated will be taken before the treatment.
Local anesthesia will be applied. Cavity preparations will be performed using diamond burs at high speed with water-cooling. Hand instruments and slow-speed tungsten carbide burs were used to remove the caries. Conservative cavity design will be used and beveling will not applied to the cavity walls to avoid unnecessary loss of hard dental tissue. The outline shape of the cavity will be limited to the removal of caries lesion. Any additional retention will not be prepared. The cavity will be rinsed and then dried with cotton pellets. A metal matrix band and wedges will be applied. Cotton rolls and a saliva ejector will be used for isolation.
Group 1 Giomer; Beautifil flow plus x After caries tissue removal, the cavity will be washed by rubbing wet cotton pellets against its walls to remove debris and remnants of decayed tissue removal. In the presence of the adjacent tooth, a matrix band and a wooden wedge were placed to adapt the restoration. A thin layer of the one-step self-etch adhesive BeautiBond (Shofu Inc) will be applied with a micro applicator and light cured for 10 s. The operator will place the Beautifil-flow plus x in increments creating the desired shape. Each increment will be light-cured for 20 s at each restoration surface. The composite will be used in increments up to 2 mm. An articulation paper will be used to check if there is any interference.
Group 2 Glass-hybrid-added HVGIC; Equia Forte:
The cavity will be conditioned with a poly- acrylic acid 'dentin conditioner' (EQUIA GC, JAPAN) which will be left for 15 seconds according to the manufacturer instructions. The conditioner will later be washed with a water spray, and then rinsing water will be blotted with a dry cotton pellet, leaving a moist surface. Each capsule of high viscous glass ionomer cement will be mixed for 10 seconds using amalgamator according to the manufacturer's instructions then packed into the prepared cavity with a carver and ball burnisher. Any excess material will be removed using a carver. Finally, a thin layer of the Equia Forte Coat ® (GC Corp) will be applied with a micro applicator and then light-cured for 20 s. An articulation paper will be used to check if the restoration caused any occlusal interference.
Inclusion Criteria:
inclusion criteria of study participants:
inclusion criteria of teeth:
Exclusion Criteria:
exclusion criteria of study participants
exclusion criteria of teeth
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
injectable flowable restorative material
Procedure: restoration of proximal cavities of primary molars with flowable giomer
Glass-hybrid-added Highly viscous glass ionomer cement
Procedure: restoration of proximal cavities of primary molars with highly viscous glass ionomer cement
removal of proximal caries of primary molars and restoration of the cavities prepared by beautifil flow plus x
removal of proximal caries of primary molars and restoration of the cavities prepared by equia forte
The clinical performance of Flowable Giomer Beautifil Flow Plus X (Shofu Dental Corporation, Japan) and Glass-hybrid-added HVGIC, Equia Forte (GC Corporation, Tokyo, Japan) in restoring class II cavities of primary molars
The restorations will be evaluated using the FDI criteria having esthetic, functional, and biological properties
Time frame: 12 months
The effect of different independent variables on the treatment outcome of the experimental restorative materials.
assessment of the effect of different variables such as the age of the patient and the properties of the tooth on the restoration survival
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2022 (actual). Primary completion is estimated for Jun 2024, 18 months after the start.
Of 470 non-industry interventional studies with no phase under Dental Caries, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's planned 18 months is above that.
Counting every sponsor, half of 503 studies reached it within 15 months; a quarter within 7 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.